Combination Chemotherapy Plus Sargramostim in Treating Patients With Cancer of the Uterus
Status:
Terminated
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so
they stop growing or die. Colony-stimulating factors such as sargramostim may increase the
number of immune cells found in bone marrow or peripheral blood and may help a person's
immune system recover from the side effects of chemotherapy.
PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy plus
sargramostim in treating patients who have advanced, persistent, or recurrent cancer of the
uterus.